Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
Provided By GlobeNewswire
Last update: Mar 6, 2024
- Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and beta-thalassemia
